Monitoring Patients on Therapy for Recurrent Endometrial Cancer

Kjersten Dosumu, DNP, MS, AGPCNP-BC, explains why investigators are optimistic about treating uterine leiomyosarcoma with olaparib and temozolomide.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Relacorilant in combination with nab-paclitaxel did not meet the statistical significance threshold for progression-free survival vs nab-paclitaxel alone.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The FDA has approved dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient, as determined by an FDA-approved test, or microsatellite instability-high.

Patients with TP53 wild-type endometrial cancer experienced a median progression-free survival of 27.4 months vs 5.2 months with placebo.